Peptides DB
Research-centric peptide and protocol reference hub
Study 24 of 24Adamax literatureCytotechnology · Observational2023

Vanillin attenuated ferroptosis in ropivacaine-induced SH-SY5Y cells by targeting phosphodiesterase 4B.

Vanillin may reduce neurotoxicity caused by ropivacaine in SH-SY5Y cells by targeting PDE4B, but further research is needed to confirm these effects in clinical settings.

Read at CytotechnologyAdd to compare

Where it sits

this study against the rest of the adamax corpus
5
Preclinical
17
Observational · this one
0
Open-label
1
Randomised
1
Reviews

Summary and findings

This study investigated the effects of vanillin on ropivacaine-induced ferroptosis in SH-SY5Y human neuroblastoma cells. The doses of vanillin used were 50 and 100 nM. The findings indicated that vanillin dose-dependently reversed reductions in cell viability and proliferation caused by ropivacaine.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2023

Abstract

The authors’ words, as Cytotechnology supplied them

Ropivacaine, a widely used local anesthetic, can induce neurotoxicity at high concentrations, but effective interventions remain limited, and ferroptosis has been implicated in this process. Vanillin, a natural phenolic compound with neuroprotective properties, was investigated for its effects on ropivacaine-induced ferroptosis in SH-SY5Y human neuroblastoma cells. An in vitro model of neurotoxicity was established using 5 mM ropivacaine, and vanillin (50 and 100 nM) dose-dependently reversed ropivacaine-induced reductions in cell viability and proliferation, suppressed lipid peroxidation markers (MDA, ROS, 4-HNE) and iron accumulation, replenished GSH levels, and restored the expression of anti-ferroptotic proteins GPX4, SLC7A11, and FTH1 while downregulating TFR1. Computational target prediction and molecular docking identified phosphodiesterase 4B (PDE4B) as a candidate binding target of vanillin. Mechanistically, vanillin promoted proteasome-dependent degradation of PDE4B without altering its mRNA expression, as demonstrated by the reversal of vanillin-induced PDE4B downregulation by the proteasome inhibitor MG132. Vanillin also suppressed ropivacaine-induced upregulation of TLR4 and p38 MAPK phosphorylation. Crucially, PDE4B overexpression abolished the protective effects of vanillin, reinstating lipid peroxidation, iron overload, GSH depletion, and the aberrant expression of ferroptosis-related proteins. Collectively, these findings demonstrate that vanillin attenuates ropivacaine-induced ferroptosis in SH-SY5Y cells by targeting PDE4B for proteasomal degradation and inhibiting the downstream TLR4/p38 MAPK signaling pathway, identifying vanillin as a promising neuroprotective agent and PDE4B as a potential therapeutic target for local anesthetic-induced neurotoxicity.<h4>Supplementary information</h4>The online version contains supplementary material available at https://doi.org/10.1007/s10616-026-01119-z.

Background

This paper addresses the neurotoxic effects of ropivacaine, a local anesthetic, and the role of ferroptosis in this process. Previous research has indicated that ferroptosis contributes to neuronal injury, but effective interventions are limited. The study explores vanillin, a natural compound with neuroprotective properties, as a potential therapeutic agent against ropivacaine-induced neurotoxicity.

Methods

An in vitro model was established using SH-SY5Y human neuroblastoma cells exposed to 5 mM ropivacaine. Vanillin was administered at doses of 50 and 100 nM. The study assessed cell viability, proliferation, lipid peroxidation markers, GSH levels, and the expression of ferroptosis-related proteins.

Results

Vanillin dose-dependently reversed the reductions in cell viability and proliferation induced by ropivacaine. It also suppressed markers of lipid peroxidation and iron accumulation, replenished GSH levels, and restored the expression of anti-ferroptotic proteins. The study identified PDE4B as a target of vanillin, with its overexpression negating vanillin's protective effects.

Interpretation

The findings suggest that vanillin may have a protective role against ferroptosis induced by ropivacaine, aligning with previous literature on the neuroprotective effects of natural compounds. However, the clinical significance of these findings remains uncertain, as the study is limited to in vitro conditions and the effect sizes were not quantified. The reliance on a single cell line and absence of in vivo data further confound the conclusions.

Key findings

  • Vanillin at 50 and 100 nM reversed ropivacaine-induced reductions in cell viability and proliferation.
  • Vanillin suppressed lipid peroxidation markers (MDA, ROS, 4-HNE) and iron accumulation.
  • Vanillin replenished GSH levels and restored the expression of anti-ferroptotic proteins GPX4, SLC7A11, and FTH1.
  • PDE4B overexpression abolished the protective effects of vanillin, reinstating lipid peroxidation and iron overload.

Limitations

  • In vitro study, results may not translate to in vivo conditions.
  • Limited to SH-SY5Y cells, which may not represent all neuronal types.
  • No quantitative effect sizes reported for the observed outcomes.
  • Single-site study with no clinical trial data.

Elsewhere in the Adamax corpus

CNeuroprotective effects of quercetin in animal models of neurodegenerative diseases: A systematic review and meta-analysis.Journal of the science of food and agriculture · 2026 · Not reported in abstract.reviewCA peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.Nature medicine · 2003 · more than 90% reduction in lesion volume at 14 d post-occlusion in adult miceAnimalBEffects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.JAMA · 2009 · 53.8% decrease in [(11)C]cocaine binding potential in caudate, 95% CI, 43.9% to 63.6%; P < .001HumanAMagnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial.Lancet (London, England) · 2012 · Risk ratio [RR] 1.03, 95% CI 0.85-1.25.HumanBPrevalence, knowledge, attitudes, and practices regarding cognitive enhancer use in a convenience sample of university students in Syria: a cross-sectional study.Annals of medicine · 2026 · n=707 · 14.6% (103/707) reported lifetime CE use.HumanCMgSO<sub>4</sub> alleviates anxiety-like behaviours in mice after traumatic brain injury by inhibiting astrocytic TRPM7 in the amygdala.Journal of psychiatric research · 2026 · Not reported in abstract.Animal